Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Brodsky

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
The American Journal of Managed Care|April 10, 2009
Fesoterodine: a new agent for treating overactive bladderPamela Ellsworth, Sandra J Berriman, Marina Brodsky
Brain Research. Molecular Brain Research|June 28, 2003
Region-specific changes in NMDA receptor mRNA induced by chronic morphine treatment are prevented by the co-administration of the competitive NMDA receptor antagonist LY274614Hongbo Zhu, Marina Brodsky, A Laurel Gorman, et al.
European Urology|December 17, 2008
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockersChristopher Chapple, Sender Herschorn, Paul Abrams, et al.
BJU International|November 6, 2009
Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstructionClaudius Füllhase, Roberto Soler, Christian Gratzke, et al.
The Journal of Urology|July 20, 2010
Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstructionClaudius Füllhase, Roberto Soler, Christian Gratzke, et al.
BJU International|May 26, 2010
Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentrationChristopher R Chapple, Sender Herschorn, Paul Abrams, et al.
Pain|June 1, 1995
Dextromethorphan suppresses both formalin-induced nociceptive behavior and the formalin-induced increase in spinal cord c-fos mRNAKathryn J Elliott, Marina Brodsky, Alexandra D Hynansky, et al.
Current Medical Research and Opinion|November 27, 2008
Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*Sender Herschorn, John Heesakkers, David Castro-Diaz, et al.
BJU International|July 24, 2008
Comparison of fesoterodine and tolterodine in patients with overactive bladderChristopher R Chapple, Philip E Van Kerrebroeck, Klaus-Peter Jünemann, et al.
BJU International|February 6, 2010
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trialSender Herschorn, Steven Swift, Zhonghong Guan, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The American Journal of Managed Care|April 10, 2009
Fesoterodine: a new agent for treating overactive bladderPamela Ellsworth, Sandra J Berriman, Marina Brodsky
Brain Research. Molecular Brain Research|June 28, 2003
Region-specific changes in NMDA receptor mRNA induced by chronic morphine treatment are prevented by the co-administration of the competitive NMDA receptor antagonist LY274614Hongbo Zhu, Marina Brodsky, A Laurel Gorman, et al.
European Urology|December 17, 2008
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockersChristopher Chapple, Sender Herschorn, Paul Abrams, et al.
BJU International|November 6, 2009
Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstructionClaudius Füllhase, Roberto Soler, Christian Gratzke, et al.
The Journal of Urology|July 20, 2010
Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstructionClaudius Füllhase, Roberto Soler, Christian Gratzke, et al.
BJU International|May 26, 2010
Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentrationChristopher R Chapple, Sender Herschorn, Paul Abrams, et al.
Pain|June 1, 1995
Dextromethorphan suppresses both formalin-induced nociceptive behavior and the formalin-induced increase in spinal cord c-fos mRNAKathryn J Elliott, Marina Brodsky, Alexandra D Hynansky, et al.
Current Medical Research and Opinion|November 27, 2008
Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*Sender Herschorn, John Heesakkers, David Castro-Diaz, et al.
BJU International|July 24, 2008
Comparison of fesoterodine and tolterodine in patients with overactive bladderChristopher R Chapple, Philip E Van Kerrebroeck, Klaus-Peter Jünemann, et al.
BJU International|February 6, 2010
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trialSender Herschorn, Steven Swift, Zhonghong Guan, et al.
Pageof 3